A reverse
(226)Th
(230)U/(226)Th radionuclide generator
Targeted alpha therapy
Journal
Nuclear medicine and biology
ISSN: 1872-9614
Titre abrégé: Nucl Med Biol
Pays: United States
ID NLM: 9304420
Informations de publication
Date de publication:
Historique:
received:
28
07
2020
revised:
23
09
2020
accepted:
28
09
2020
pubmed:
18
10
2020
medline:
28
9
2021
entrez:
17
10
2020
Statut:
ppublish
Résumé
Thorium-226 (half-life 30.6 m) is a radionuclide of interest for use in targeted alpha therapy applications. Due to its short half-life, A reverse radionuclide generator system was developed employing a DGA extraction chromatography column. A Thorium-226 was recovered from the radionuclide generator column with >96% yield. Greater than 99.5% of the The reverse radionuclide generator described herein was shown to be a feasible method for providing
Identifiants
pubmed: 33068963
pii: S0969-8051(20)30215-8
doi: 10.1016/j.nucmedbio.2020.09.006
pii:
doi:
Substances chimiques
Thorium-226
0
Uranium-230
0
Uranium
4OC371KSTK
Thorium
60YU5MIG9W
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
69-73Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.